Emergent Biosolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent Biosolutions Inc. on January 16, 2018. The report addresses capital structure changes and share counts as of December 31, 2017.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on equity capitalization details.
Material Changes
As of December 31, 2017, the company reported the following changes to its capital structure:
- Convertible Note Conversion: Issuance of 8,508,056 shares of common stock to holders of the 2.875% Convertible Senior Notes due 2021.
- Stock Repurchase: Repurchase of 788,894 shares under the company's stock repurchase program.
- Share Counts: Total shares issued were 50,619,808, and total shares outstanding were 49,405,365.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, contingencies, or unusual items beyond the share count updates.
Investor Verification Checklist
- Verify the impact of the 8.5 million share issuance on earnings per share (EPS) dilution.
- Confirm the remaining balance of the 2.875% Convertible Senior Notes due 2021 following the conversion.
- Review the remaining authorization and activity under the stock repurchase program.
- Check subsequent filings for the official 2017 annual financial results (10-K) to obtain revenue and profit data.